Pfizer Logo
US7170811035
852009
PFE

Pfizer

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è +24,19 (+0,25%). La mediana è +23,61 (2,15%).

Acquista
  15
Mantieni
  23
Vendi
  1

  • Pfizer's dividend supported now but cash demands pose rising risk

    Pfizer yields about 6.1% but its dividend payout exceeds 200% of earnings; measured against free cash flow the cash dividend payout ratio is roughly 90%. The company holds about $1 billion in cash and $10.7 billion in short-term investments and pays roughly $2.5 billion in dividends each quarter, so the payout is covered today. Main near-term risks are patent expirations and higher R&D needs that will compete with the same cash pool supporting the dividend. » Altro su finance.yahoo.com


  • Pfizer yields 6% as stock trades at discount amid debt and patent headwinds

    Pfizer's shares have tumbled about 38% over five years as COVID-19 revenues collapsed and key drugs face patent cliffs, while acquisitions such as Seagen and Metsera pushed net debt above $53 billion. Despite these challenges, Pfizer generated nearly $11 billion in free cash flow over the last twelve months and saw 21% revenue growth from Seagen's cancer portfolio. The stock's 6% dividend yield reflects the discount, and the payout could remain sustainable if Pfizer reduces debt and grows through acquisitions and its pipeline. » Altro su finance.yahoo.com


  • Pfizer posts modest operational growth as new drugs and cost cuts drive recovery

    Pfizer reported 1% operational revenue growth in Q2 2026 to $15.0 billion, with revenue excluding Comirnaty and Paxlovid up 5% and launched/acquired products generating $3.2 billion (up 18% operationally). Padcev and the Vyndaqel family posted strong gains, while management raised the midpoint of full-year guidance and expects about $5.7 billion in net savings by end-2026. The company remains exposed to looming patent expirations on drugs such as Eliquis, Ibrance and Xtandi, with an estimated $1.1 billion unfavorable revenue impact in 2026 from generics and biosimilars, leaving uncertainty whether new products can fully offset lost franchise revenue. » Altro su finance.yahoo.com

Nel 2026, Pfizer ha già distribuito +0,74 di dividendi. L'ultimo pagamento è avvenuto a giugno.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Pfizer ha registrato ricavi pari a +13,20Mld e un utile netto di 216,05M
(EUR) giu 2026
YoY
Ricavi +13,20Mld 5,67%
Utile lordo +9,61Mld 19,63%
Utile netto 216,05M 108,71%
EBITDA +1,05Mld 76,80%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
+139,82Mld
Numero di azioni
5,70Mld
Massimo/minimo a 52 settimane
+24,69 - +20,25
Rendimento da dividendo
+6,09%
Dividendi TTM
+1,48
Prossimo dividendo
+0,37
Beta
0,28
Rapporto P/E
+37,75
Rapporto PEG
0,63
Rapporto P/B
+1,91
Rapporto P/S
+2,56

Profilo aziendale

Pfizer Inc. erforscht, entwickelt, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Das Unternehmen bietet Medikamente und Impfstoffe in verschiedenen therapeutischen Bereichen an, darunter Herz-Kreislauf-Stoffwechsel- und Frauengesundheit unter den Marken Premarin und Eliquis; Biologika, kleine Moleküle, Immuntherapien und Biosimilars unter den Marken Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena und Braftovi; und sterile injizierbare und antiinfektiöse Arzneimittel sowie orale COVID-19-Behandlung unter den Marken Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga und Paxlovid. Das Unternehmen bietet auch Arzneimittel und Impfstoffe in verschiedenen therapeutischen Bereichen an, wie Pneumokokken, Meningokokken, Zeckenenzephalitis und COVID-19 unter den Marken Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba und der Prevnar-Familie; Biosimilars für chronische Immun- und Entzündungskrankheiten unter den Marken Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis und Cibinqo sowie Amyloidose, Hämophilie und endokrine Erkrankungen unter den Marken Vyndaqel/Vyndamax, BeneFIX und Genotropin. Darüber hinaus ist das Unternehmen im Bereich der Auftragsherstellung tätig. Das Unternehmen beliefert Großhändler, Einzelhändler, Krankenhäuser, Kliniken, Behörden, Apotheken und einzelne Anbieter sowie Zentren für Krankheitskontrolle und Prävention. Das Unternehmen hat Kooperationsvereinbarungen mit Bristol-Myers Squibb Company, Astellas Pharma US, Inc, Myovant Sciences Ltd, Akcea Therapeutics, Inc, Merck KGaA, Valneva SE, BioNTech SE und Arvinas, Inc. Pfizer Inc. wurde 1849 gegründet und hat seinen Hauptsitz in New York, New York.

Nome
Pfizer
CEO
Albert Bourla
Sede centrale New York City, ny
Stati Uniti
Sito web
Settore
Sanità
Industria
Prodotti farmaceutici
Quotazione in borsa
26/02/2021
Dipendenti 75.000

Simboli di borsa

Borsa Simbolo
NYSE
PFE
XETRA
PFE.DE
XETRA
PFE.F
Frankfurt
PFE.F
Düsseldorf
PFE.DU
Hamburg
PFE.HM
Milan
1PFE.MI
London
0Q1N.L
SIX
PFE.SW
München
PFE.MU
Wien
PFE.VI
🍪

Parqet  usa i cookie. Scopri di più